Next Article in Journal
Death Receptor 5 (TNFRSF10B) Is Upregulated and TRAIL Resistance Is Reversed in Hypoxia and Normoxia in Colorectal Cancer Cell Lines after Treatment with Skyrin, the Active Metabolite of Hypericum spp.
Next Article in Special Issue
Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature
Previous Article in Journal
Expression of SEC62 Oncogene in Benign, Malignant and Borderline Melanocytic Tumors—Unmasking the Wolf in Sheep’s Clothing?
Previous Article in Special Issue
Evolution of Surgical Treatment of Colorectal Liver Metastases in the Real World: Single Center Experience in 1212 Cases
Review

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review

1
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea
2
Department of Surgery, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul 06351, Korea
3
Division of Hematology and Oncology, Department of Internal Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul 06351, Korea
4
Department of Surgery, Asan Medical Center, College of Medicine, University of Ulsan, Seoul 05505, Korea
5
Department of Radiation Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul 05505, Korea
*
Authors to whom correspondence should be addressed.
These authors equally contributed to this work.
Academic Editors: Matias A. Avila, Carmen Berasain and Andrea Casadei-Gardini
Cancers 2021, 13(7), 1647; https://doi.org/10.3390/cancers13071647
Received: 14 February 2021 / Revised: 27 March 2021 / Accepted: 27 March 2021 / Published: 1 April 2021
(This article belongs to the Special Issue Theranostic Advances in Hepatobiliary Tumors)
For decades, there has been no globally accepted neoadjuvant or adjuvant therapy in resectable biliary tract cancer. Based on the results of the BILCAP trial, adjuvant capecitabine has been widely regarded as standard adjuvant therapy. Focusing on the management of resectable biliary tract cancer, this article reviews each therapeutic strategy including surgery, chemotherapy and radiotherapy, and summarises published and ongoing clinical trials of neoadjuvant and adjuvant therapy.
Biliary tract cancers (BTCs) are a group of aggressive malignancies that arise from the bile duct and gallbladder. BTCs include intrahepatic cholangiocarcinoma (IH-CCA), extrahepatic cholangiocarcinoma (EH-CCA), and gallbladder cancer (GBCA). BTCs are highly heterogeneous cancers in terms of anatomical, clinical, and pathological characteristics. Until recently, the treatment of resectable BTC, including surgery, adjuvant chemotherapy, and radiation therapy, has largely been based on institutional practice guidelines and evidence from small retrospective studies. Recently, several large randomized prospective trials have been published, and there are ongoing randomized trials for resectable BTC. In this article, we review prior and recently updated evidence regarding surgery, adjuvant and neoadjuvant chemotherapy, and adjuvant radiation therapy for patients with resectable BTC. View Full-Text
Keywords: biliary tract cancer; cholangiocarcinoma; gallbladder cancer; adjuvant chemotherapy; radiation therapy; surgery biliary tract cancer; cholangiocarcinoma; gallbladder cancer; adjuvant chemotherapy; radiation therapy; surgery
Show Figures

Figure 1

MDPI and ACS Style

Yoo, C.; Shin, S.H.; Park, J.-O.; Kim, K.-P.; Jeong, J.H.; Ryoo, B.-Y.; Lee, W.; Song, K.-B.; Hwang, D.-W.; Park, J.-h.; Lee, J.H. Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. Cancers 2021, 13, 1647. https://doi.org/10.3390/cancers13071647

AMA Style

Yoo C, Shin SH, Park J-O, Kim K-P, Jeong JH, Ryoo B-Y, Lee W, Song K-B, Hwang D-W, Park J-h, Lee JH. Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. Cancers. 2021; 13(7):1647. https://doi.org/10.3390/cancers13071647

Chicago/Turabian Style

Yoo, Changhoon, Sang H. Shin, Joon-Oh Park, Kyu-Pyo Kim, Jae H. Jeong, Baek-Yeol Ryoo, Woohyung Lee, Ki-Byung Song, Dae-Wook Hwang, Jin-hong Park, and Jae H. Lee 2021. "Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review" Cancers 13, no. 7: 1647. https://doi.org/10.3390/cancers13071647

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop